Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support

References

• Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. the German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
   PubMed Web of Science ®Google Scholar
• Canellos G P, Anderson J R, Propert K J, Nissen N, Cooper M R, Henderson E S, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Duggan D B, Petroni G R, Johnson J L, Glick J H, Fisher R I, Connors J M, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607–614
   PubMed Web of Science ®Google Scholar
• Johnson P W, Radford J A, Cullen M H, Sydes M R, Walewski J, Jack A S, et al. United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23: 9208–9218
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22: 2835–2841
   PubMed Web of Science ®Google Scholar
• Carde P, Mackintosh F R, Rsenberg S A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146–153
   PubMed Web of Science ®Google Scholar
• Bezwoda W R, Dansey R, Bezwoda M A. Treatment of Hodgkin's disease with MOPP chemotherapy: effect of dose and schedule modification on treatment outcome. Oncology 1990; 47: 29–36
   PubMed Web of Science ®Google Scholar
• van Rijswijk R E, Haanen C, Dekker A W, de Meijer A J, Verbeek J. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989; 7: 1776–1782
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–170
   PubMed Web of Science ®Google Scholar
• Pettengell R, Gurney H, Radford J A, Deakin D P, James R, Wilkinson P M, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Silvestri F, Fanin R, Velisig M, Barillari G, Virgolini L, Zaja F, et al. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. Tumor 1994; 80: 453–458
   PubMed Web of Science ®Google Scholar
• Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006; 42: 2976–2981
   PubMed Web of Science ®Google Scholar
• Rueda A, Sevilla I, Gumà J, Ribelles N, Miramón J, De Las Nieves M A, et al. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. Leuk Lymphoma 2001; 41: 353–358
   PubMed Web of Science ®Google Scholar
• Gustavsson A. G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. Acta Oncol 1997; 36: 483–488
   PubMed Web of Science ®Google Scholar
• Lister T A, Crowther D, Sutcliffe S B, Glatstein E, Canellos G P, Young R C. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. For the international prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998; 19: 1506–1514
   Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244, Review. Erratum in: J Clin Oncol 2000;18:2351
   PubMed Web of Science ®Google Scholar
• Chand V K, Link B K, Ritchie J M, Shannon M, Wooldridge J E. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leuk Lymphoma 2006; 47: 657–663
   PubMed Web of Science ®Google Scholar
• Schaefer N G, Taverna C, Strobel K, Wastl C, Kurrer M, Hany T F. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy – is biopsy of FDG-avid lesions still needed?. Radiology 2007; 244: 257–262
   PubMed Web of Science ®Google Scholar
• Goldie J H, Coldman A J. Goldie qualitative model for multiple levels of drug resistance in clinical tumours. Cancer Treatment Reports 1983; 67: 923–931
   PubMedGoogle Scholar
• Bodey G P, Buckley M, Sathe Y S, Freireich E J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328
   PubMed Web of Science ®Google Scholar
• Bow E J. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 1998; 41(Suppl D)1–5, Review
   PubMed Web of Science ®Google Scholar
• Aglietta M, Montemurro F, Fagioli F, Volta C, Botto B, Cantonetti M, et al. Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. Cancer 2000; 88: 454–460
   PubMed Web of Science ®Google Scholar
• Riccardi A, Gobbi P, Danova M, Giordano M, Pieresca C, Bertoloni D, et al. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease. Haematologica 1993; 78: 44–48
   PubMed Web of Science ®Google Scholar
• Dunlop D J, Eatock M M, Paul J, Anderson S, Reed N S, Soukop M, et al. Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) 1998; 10: 107–114
   PubMedGoogle Scholar
• Boleti E, Mead G M. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007; 18: 376–380
   PubMed Web of Science ®Google Scholar
• Evens A M, Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007; 137: 545–552
   PubMed Web of Science ®Google Scholar
• Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003; 122: 413–423, Review
   PubMed Web of Science ®Google Scholar
• Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004; 1: CD003189, Review
   PubMedGoogle Scholar
• Aapro M S, Cameron D A, Pettengell R, Bohlius J, Crawford J, Ellis M. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433–2453, Review
   PubMed Web of Science ®Google Scholar
• Smith T J, Khatcheressian J, Lyman G H, Ozer H, Armitage J O, Balducci L. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205
   PubMed Web of Science ®Google Scholar
• Martin W G, Ristow K M, Habermann T M, Colgan J P, Witzig T E, Ansell S M. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23: 7614–7620
   PubMed Web of Science ®Google Scholar